Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021956 · ClinicalTrials.gov registry record · Phase 2
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
A Phase 2 study, sponsored by Steba Biotech S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01021956 is a Phase 2 study that was terminated before completion, run by Steba Biotech S.A.. The registered enrollment target is 10 participants.
The verdict
NCT01021956, a Phase 2 study, was terminated before completion, sponsored by Steba Biotech S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12 weeks after VTP. All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events (AEs) collection).
Interventions
- DRUG STAKEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021956
The ClinicalTrials.gov registry entry for NCT01021956 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steba Biotech S.A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STAKEL is the first listed.
NCT01021956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01021956 about?
NCT01021956 is a clinical study titled "Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD". The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelen...
What is the current status of trial NCT01021956?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-06. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01021956?
The interventions under investigation include: STAKEL (DRUG).
Who is sponsoring clinical trial NCT01021956?
This trial is sponsored by Steba Biotech S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.